ABSTRACT
Objective To explore factors influencing primary dysfunction of autologous arteriovenous fistula (AVF) in patients with maintenance hemodialysis (MHD).
Methods This is a retrospectively study. One hundred and twenty-one patients who underwent anastomosis for AVF in our hospital Between 1st January 2016 and 31st December 2018 were selected. Seventy-seven patients satisfied the inclusion criteria and were included in the final analyses. Patients were divided into two groups based on the function of vascular access. The comparisons of complete blood count and other blood biochemical parameters were made between two groups. Factors influencing AVF dysfunction were analyzed by multivariate Cox proportional hazard regression model for patients with End stage renal disease (ESRD).
Results There were significant differences in total cholesterol (TC), low density lipoprotein (LDL) and serum phosphorus levels between patency and dysfunction group (P<0.05) of AVFs. Further multivariate COX proportional risk regression showed that hypercholesterolemia and hyperphosphatemia were independent risk factors for AVF dysfunction.
Conclusions Hypercholesterolemia and hyperphosphatemia are independent risk factors for primary AVF dysfunction in patients with MHD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no financial support for the research, authorship, and/or publication of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committee of Xuanwu Hospital, Capital Medical University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anyone who wants to use the data in the text will need to be consented by the authors
